For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Boston Scientific (BSX) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Boston Scientific is one of 1025 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Boston Scientific is currently sporting a Zacks Rank of #2 (Buy). Over the past 90 days, the Zacks Consensus Estimate for BSX's full-year earnings has moved 3.1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving. According to our latest data, BSX has moved about 35.2% on a year-to-date basis. In comparison, Medical companies have returned an average of 8.3%. This shows that Boston Scientific is outperforming its peers so far this year. Another stock in the Medical sector, Novavax (NVAX), has outperformed the sector so far this year. The stock's year-to-date return is 242.5%. Over the past three months, Novavax's consensus EPS estimate for the current year has increased 158.8%. The stock currently has a Zacks Rank #2 (Buy). Breaking things down more, Boston Scientific is a member of the Medical - Products industry, which includes 88 individual companies and currently sits at #102 in the Zacks Industry Rank. On average, this group has gained an average of 3.6% so far this year, meaning that BSX is performing better in terms of year-to-date returns. Novavax, however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 500-stock industry is ranked #73. The industry has moved +0.9% so far this year. Investors with an interest in Medical stocks should continue to track Boston Scientific and Novavax. These stocks will be looking to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX):Free Stock Analysis Report Novavax, Inc. (NVAX):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...